Paolo Tarantino, MD, PhD, is a clinical research fellow at Dana-Farber Cancer Institute.
Understanding How On-Target and Off-Target ADC Toxicities Work
Paolo Tarantino, MD, PhD, explains that the chemotherapy-related toxicities from an ADC are more likely to limit dosage for patients with cancer.
ADCs Are “Legos,” Customize Cancer Treatment By Target, Safety
Each component of an antibody-drug conjugates—payload, linker, and antibody—play a unique role in building the treatment’s use and safety profile.
Managing CRS in Hematologic Cancers: A Nursing Perspective
Safer Care in Breast Cancer: Expert Advice for Managing ADC Toxicities
How Nurses Can Assess and Manage Talquetamab Toxicities
Transformative Care: A Nurse Guide to Novel Therapies in Blood Cancers